Nanohale AG (ETR:FYB) | Finanzwire

Basculer en Français

9480	Companies
185523	Keywords
117911	Articles
99370	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 02/25/2025 at 06:35, 9 months 8 days ago

Formycon's FYB203 Receives UK Regulatory Approval

UK Regulatory Biosimilar Approval Formycon FYB203 Ophthalmic Treatment Teva Partnership
PRESS RELEASE

published on 02/25/2025 at 06:30, 9 months 8 days ago

Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®. Approval for treating retinal diseases granted by UK's MHRA

Regulatory Approval UK Biosimilar Formycon AHZANTIVE
BRIEF

published on 02/24/2025 at 11:31, 9 months 9 days ago

Formycon AG: Price Target Adjusted Amid Market Pressures

Buy Recommendation Formycon AG Price Pressure Biosimilar Market Investment Reduction
PRESS RELEASE

published on 02/24/2025 at 11:26, 9 months 9 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates its research on Formycon AG, maintaining a Buy recommendation with a decreased target price from EUR 82 to EUR 46 due to higher price pressure and reduced investments in biosimilar portfolio

First Berlin Equity Research Buy Recommendation Research Update Formycon AG Biosimilar Portfolio
BRIEF

published on 02/20/2025 at 06:35, 9 months 13 days ago

Formycon Unveils Clinical Data for Ustekinumab Biosimilar FYB202 at ECCO Congress

Formycon AG Regulatory Approval Clinical Data Biosimilar FYB202
PRESS RELEASE

published on 02/20/2025 at 06:30, 9 months 13 days ago

Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
Formycon presents clinical data on ustekinumab biosimilar FYB202 at ECCO Congress, demonstrating comparability with Stelara. FYB202 approved in multiple regions

Clinical Data ECCO Congress Biosimilar Formycon Ustekinumab
BRIEF

published on 02/17/2025 at 09:32, 9 months 16 days ago

Formycon AG Updates on Biosimilar Projects and Strategic Adjustments

FDA Approval Biosimilars Financial Adjustments Commercial Strategy Price Discounts
PRESS RELEASE

published on 02/17/2025 at 09:27, 9 months 16 days ago

Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
Formycon AG provides updates on various biosimilar projects, including terminating phase III trial for FYB206. Conference call on Feb 17, 2025, to discuss recent developments

FDA Conference Call Formycon AG FYB206 Biosimilar Projects
BRIEF

published on 02/17/2025 at 08:10, 9 months 16 days ago

Formycon Updates on Phase III Trial and Valuation Adjustments

Formycon AG FDA Feedback Phase III Trial Commercialization Strategy Biosimilar Valuation
PRESS RELEASE

published on 02/17/2025 at 08:05, 9 months 16 days ago

EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
Formycon terminates Phase III trial for FYB206 after FDA feedback, anticipates valuation adjustments for FYB202 & FYB201 due to price discounts

FDA Feedback Valuation Adjustments Formycon FYB206 Price Discounts

Accesswire

Published on 12/05/2025 at 18:20, 15 minutes ago

NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 35 minutes ago

SMX: A New Supply Chain Reality in the World's Four Largest Markets
Published on 12/05/2025 at 17:15, 1 hour 20 minutes ago

TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 17:00, 1 hour 35 minutes ago

Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once
Published on 12/05/2025 at 16:00, 2 hours 35 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:26, 8 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 19 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 43 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 49 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:00, 1 hour 35 minutes ago

EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance

Les Echos

Published on 12/05/2025 at 17:18, 1 hour 17 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 3 hours 24 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 9 hours 50 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 1 day ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 1 day ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE